Regulation of Bcl-2 expression by HuR in HL60 leukemia cells and A431 carcinoma cells

Molecular Cancer Research

Volumn 7, Issue 8, 2009, Pages 1354-1366

  Ishimaru, Daniella ^a   Ramalingam, Sivakumar ^a   Sengupta, Tapas K ^a,c   Bandyopadhyay, Sumita ^a,d   Dellis, Stephanie ^b   Tholanikunnel, Baby G ^a   Fernandes, Daniel J ^a   Spicer, Eleanor K ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b School of Business   (United States)

^c INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH KOLKATA   (India)

^d UNIVERSITY OF CALCUTTA   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CELL EXTRACT; HUR PROTEIN; MESSENGER RNA; NUCLEAR RNA; NUCLEOLIN; PROTEIN BCL 2; RIBONUCLEOPROTEIN;

ARTICLE; BINDING SITE; CARCINOMA CELL; CELL PROTECTION; CELL STRAIN HL 60; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; POLYSOME; PRECIPITATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STABILITY; TRANSLATION INITIATION;

ANTIGENS, SURFACE; CARCINOMA, SQUAMOUS CELL; CENTRIFUGATION, DENSITY GRADIENT; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HL-60 CELLS; HUMANS; IMMUNOPRECIPITATION; LEUKEMIA; PHOSPHOPROTEINS; POLYRIBOSOMES; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-BCL-2; RECOMBINANT PROTEINS; REGULATORY SEQUENCES, RIBONUCLEIC ACID; RNA STABILITY; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS;

EID: 69449107823     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0476     Document Type: Article

References (66)

1. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335:440-442 (Pubitemid 18234863)
2. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-619 (Pubitemid 23259742)
3. Chittenden T, Harrington EA, O'Connor R, et al. Induction of apoptosis by the Bcl-2 homologue Bak. Nature 1995;374:733-736
4. Yang E, Zha J, Jockel J, et al. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995;80:285-291
5. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998;281:1322-1326 (Pubitemid 28406819)
6. Nahta R, Esteva FJ. Bcl-2 antisense oligonucleotides: a potential novel strategy for the treatment of breast cancer. Semin Oncol 2003;30:143-149 (Pubitemid 37433405)
7. Steube KG, Jadau A, Teepe D, et al. Expression of bcl-2 mRNA and protein in leukemia-lymphoma cell lines. Leukemia 1995;9:1841-1846
8. Otake Y, Soundararajan S, Sengupta TK, et al. Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA. Blood 2007;109:3069-3075 (Pubitemid 46482108)
9. Reed JC. Bcl-2 family proteins: strategies for overcoming chemoresistance in cancer. Adv Pharmacol 1997;41:501-532
10. Gao G, Dou QP. G1 phase-dependent expression of bcl-2 mRNA and protein correlates with chemoresistance of human cancer cells. Mol Pharmacol 2000;58:1001-1010 (Pubitemid 30800790)
11. Seto M, Jaeger U, Hockett RD, et al. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J 1988;7:123-131
12. Soundararajan S, Chen W, Spicer EK, et al. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res 2008;68:2358-2365
13. Dyer MJ, Zani VJ, Lu WZ, et al. BCL2 translocations in leukemias of mature B cells. Blood 1994;83:3682-3688
14. Bakhshi A, Jensen JP, Goldman P, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985;41:899-906. (Pubitemid 15243395)
15. Robertson LE, Plunkett W, McConnell K, et al. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 1996;10:456-459 (Pubitemid 26128784)
16. Majid A, Tsoulakis O, Walewska R, et al. BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938A > C promoter single nucleotide polymorphism. Blood 2008;111:874-877
17. Chen CY, Shyu AB. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci 1995;20:465-470
18. Bandyopadhyay S, Sengupta TK, Fernandes DJ, et al. Taxol- and okadaic acid-induced destabilization of bcl-2 mRNA is associated with decreased binding of proteins to a bcl-2 instability element. Biochem Pharmacol 2003;66:1151-1162 (Pubitemid 37130290)
19. Schiavone N, Rosini P, Quattrone A, et al. A conserved AU-rich element in the 3′ untranslated region of bcl-2 mRNA is endowed with a destabilizing function that is involved in bcl-2 down-regulation during apoptosis. FASEB J 2000;14:174-184 (Pubitemid 30051535)
20. Lapucci A, Donnini M, Papucci L, et al. AUF1 Is a bcl-2 A + U-rich elementbinding protein involved in bcl-2 mRNA destabilization during apoptosis. J Biol Chem 2002;277:16139-16146 (Pubitemid 34967900)
21. Otake Y, Sengupta TK, Bandyopadhyay S, et al. Retinoid-induced apoptosis in HL-60 cells is associated with nucleolin down-regulation and destabilization of Bcl-2 mRNA. Mol Pharmacol 2005;67:319-326 (Pubitemid 40069993)
22. Otake Y, Sengupta TK, Bandyopadhyay S, et al. Drug-induced destabilization of bcl-2 mRNA: a new approach for inducing apoptosis in tumor cells. Curr Opin Investig Drugs 2004;5:616-622
23. Sengupta TK, Bandyopadhyay S, Fernandes DJ, et al. Identification of nucleolin as an AU-rich element binding protein involved in bcl-2 mRNA stabilization. J Biol Chem 2004;279:10855-10863 (Pubitemid 38401575)
24. Bose SK, Sengupta TK, Bandyopadhyay S, et al. Identification of Ebp1 as a component of cytoplasmic bcl-2 mRNP (messenger ribonucleoprotein particle) complexes. Biochem J 2006;396:99-107. (Pubitemid 43764501)
25. Ma WJ, Cheng S, Campbell C, et al. Cloning and characterization of HuR, a ubiquitously expressed Elav-like protein. J Biol Chem 1996;271:8144-8151 (Pubitemid 26108641)
26. Myer VE, Fan XC, SteitzJA. Identification of HuR as a protein implicated in AUUUA-mediated mRNA decay. EMBO J 1997;16:2130-2139
27. Fialcowitz-White EJ, Brewer BY, Ballin JD, et al. Specific protein domains mediate cooperative assembly of HuR oligomers on AU-rich mRNA-destabilizing sequences. J Biol Chem 2007;282:20948-20959
28. Sengupta S, Jang BC, Wu MT, et al. The RNA-binding protein HuR regulates the expression of cyclooxygenase-2. J Biol Chem 2003;278:25227-25233 (Pubitemid 37548687)
29. Wang W, Furneaux H, Cheng H, et al. HuR regulates p21 mRNA stabilization by UV light. Mol Cell Biol 2000;20:760-769 (Pubitemid 30044212)
30. Lal A, Mazan-Mamczarz K, Kawai T, et al. Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs. EMBO J 2004;23:3092-3102 (Pubitemid 39093603)
31. Bandyopadhyay S, Sengupta TK, Spicer EK. PMA induces stabilization of oncostatin M mRNA in human lymphoma U937 cells. Biochem J 2008;410:177-186 (Pubitemid 351300337)
32. Mazan-Mamczarz K, Galban S, Lopez de Silanes I, et al. RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation. Proc Natl Acad Sci U S A 2003;100:8354-8359 (Pubitemid 36842549)
33. Katsanou V, Papadaki O, Milatos S, et al. HuR as a negative posttranscriptional modulator in inflammation. Mol Cell 2005;19:777-789 (Pubitemid 41316672)
34. Denkert C, Weichert W, Pest S, et al. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res 2004;64:189-195 (Pubitemid 38114097)
35. Heinonen M, Bono P, Narko K, et al. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res 2005;65:2157-2161 (Pubitemid 40490122)
36. Abdelmohsen K, Lal A, Kim HH, et al. Posttranscriptional orchestration of an anti-apoptotic program by HuR. Cell Cycle 2007;6:1288-1292 (Pubitemid 47327958)
37. Mili S, SteitzJA. Evidence for reassociation of RNA-binding proteins after cell lysis: implications for the interpretation of immunoprecipitation analyses. RNA 2004;10:1692-1694
38. Niranjanakumari S, Lasda E, Brazas R, et al. Reversible cross-linking combined with immunoprecipitation to study RNA-protein interactions in vivo. Methods 2002;26:182-190 (Pubitemid 34969580)
39. Nicholson-Weller A, Burge J, Fearon DT, et al. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol 1982;129:184-189 (Pubitemid 12080686)
40. Barreau C, Paillard L, Osborne HB. AU-rich elements and associated factors: are there unifying principles?. Nucleic Acids Res 2005;33:7138-7150 (Pubitemid 43125082)
41. Elferink CJ, Reiners JJ, Jr. Quantitative RT-PCR on CYP1A1 heterogeneous nuclear RNA: a surrogate for the in vitro transcription run-on assay. BioTechniques 1996;20:470-477
42. Gartner H, Shukla P, Markesich DC, et al. Developmental expression of trehalase: role of transcriptional activation. Biochim Biophys Acta 2002;1574:329-336 (Pubitemid 34457907)
43. Shyu AB, Greenberg ME, Belasco JG. The c-fos transcript is targeted for rapid decay by two distinct mRNA degradation pathways. Genes Dev 1989;3:60-72.
44. Peng SS, Chen CY, Xu N, et al. RNA stabilization by the AU-rich element binding protein, HuR, an ELAV protein. EMBO J 1998;17:3461-3470 (Pubitemid 28279518)
45. Ford LP, WiluszJ. An in vitro system using HeLa cytoplasmic extracts that reproduces regulated mRNA stability. Methods 1999;17:21-27
46. Mukherjee D, Gao M, O'Connor JP, et al. The mammalian exosome mediates the efficient degradation of mRNAs that contain AU-rich elements. EMBO J 2002;21:165-174 (Pubitemid 34087085)
47. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
48. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-681
49. Kullmann M, Gopfert U, Siewe B, et al. ELAV/Hu proteins inhibit p27 translation via an IRES element in the p27 5′UTR. Genes Dev 2002;16:3087-3099 (Pubitemid 35424195)
50. Chen CY, Xu N, Shyu AB. Highly selective actions of HuR in antagonizing AU-rich element-mediated mRNA destabilization. Mol Cell Biol 2002;22:7268-7278
51. Zubiaga AM, Belasco JG, Greenberg ME. The nonamer UUAUUUAUU is the key AU-rich sequence motif that mediates mRNA degradation. Mol Cell Biol 1995;15:2219-2230
52. Lopezde Silanes I, Zhan M, Lal A, et al. Identification of a target RNA motif for RNA-binding protein HuR. Proc Natl Acad Sci U S A 2004;101:2987-2992 (Pubitemid 38327723)
53. Williamson JR. Induced fit in RNA-protein recognition. Nat Struct Biol 2000;7:834-837
54. Leulliot N, Varani G. Current topics in RNA-protein recognition: control of specificity and biological function through induced fit and conformational capture. Biochemistry 2001;40:7947-7956 (Pubitemid 32641191)
55. Chen CY, Gherzi R, Andersen JS, et al. Nucleolin and YB-1 are required for JNK-mediated interleukin-2 mRNA stabilization during T-cell activation. Genes Dev 2000;14:1236-1248 (Pubitemid 30327504)
56. Zaidi SH, Malter JS. Nucleolin and heterogeneous nuclear ribonucleoprotein C proteins specifically interact with the 3′- untranslated region of amyloid protein precursor mRNA. J Biol Chem 1995;270:17292-17298
57. Brennan CM, SteitzJA. HuR and mRNA stability. Cell Mol Life Sci 2001;58:266-277
58. Meng Z, King PH, Nabors LB, et al. The ELAV RNA-stability factor HuR binds the 5′-untranslated region of the human IGF-IR transcript and differentially represses cap-dependent and IRES-mediated translation. Nucleic Acids Res 2005;33:2962-2979 (Pubitemid 41518704)
59. Wilson T, Treisman R. Removal of poly(A) and consequent degradation of cfos mRNA facilitated by 3′ AU-rich sequences. Nature 1988;336:396-399
60. Shyu AB, Belasco JG, Greenberg ME. Two distinct destabilizing elements in the c-fos message trigger deadenylation as a first step in rapid mRNA decay. Genes Dev 1991;5:221-231
61. Chen CY, Gherzi R, Ong SE, et al. AU binding proteins recruit the exosome to degrade ARE-containing mRNAs. Cell 2001;107:451-464 (Pubitemid 33152781)
62. Mitchell P, Petfalski E, Shevchenko A, et al. The exosome: a conserved eukaryotic RNA processing complex containing multiple 3′→5′ exoribonucleases. Cell 1997;91:457-466 (Pubitemid 27508235)
63. Dignam JD, LebovitzRM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucl Acids Res 1983;11:1475-1489
64. Yang C, Maiguel DA, Carrier F. Identification of nucleolin and nucleophosmin as genotoxic stress-responsive RNA-binding proteins. Nucleic Acids Res 2002;30:2251-2260 (Pubitemid 34567946)
65. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of realtime quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3: RESEARCH0034.
66. Kandasamy K, Joseph K, Subramaniam K, et al. Translational control of β2- adrenergic receptor mRNA by T-cell-restricted intracellular antigen-related protein. J Biol Chem 2005;280:1931-1943